The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18341
Abstract: Polatuzumab vedotin (Pola) is an antibody–drug conjugate that targets the B‐cell antigen CD79b and delivers monomethyl auristatin E (MMAE). It is approved in combination with bendamustine and rituximab (Rit) for relapsed/refractory diffuse large B‐cell lymphoma… read more here.
Keywords: rationale combination; combination; rit; pola ... See more keywords